10-Q
Quarterly Report
DAY ONE BIOPHARMACEUTICALS, INC.
DAWN
NASDAQ
CIK: 1845337
File #: 001-40431
Balance Sheet
41 line items · 2 periods
XBRL
| Item | Jun 30, 2025 | Dec 31, 2024 |
|---|---|---|
Assets | ||
Current assets: | ||
Cash and cash equivalents | 35,622,000 | 124,968,000 |
U.S. treasury securities | — | 12,947,000 |
U.S. government agency securities | 10,288,000 | 75,163,000 |
Cash equivalents | 23,857,000 | 104,838,000 |
Money market funds | 13,569,000 | 16,728,000 |
Short-term investments | 417,481,000 | 406,752,000 |
Accounts receivable, net | 19,669,000 | 13,876,000 |
Inventory | 6,543,000 | 3,321,000 |
Prepaid expenses and other current assets | 15,113,000 | 13,413,000 |
Total current assets | 494,428,000 | 562,330,000 |
Property and equipment, net | 2,317,000 | 2,285,000 |
Operating lease right-of-use asset | 2,499,000 | 2,422,000 |
Intangible assets, net | 19,610,000 | 15,630,000 |
Deposits and other long-term assets | 183,000 | 121,000 |
Total assets | 519,037,000 | 582,788,000 |
Liabilities and stockholders' equity | ||
Current Liabilities: | ||
Accounts payable | 5,090,000 | 3,262,000 |
Accrued expenses and other current liabilities | 44,131,000 | 68,625,000 |
Current portion of deferred revenue | 1,847,000 | 1,554,000 |
Current Member - License agreement with Ipsen Pharma SAS | 1,800,000 | — |
Current portion of operating lease liabilities | 153,000 | 10,000 |
Total current liabilities | 51,221,000 | 73,451,000 |
Long-term portion of deferred revenue | 3,371,000 | 3,233,000 |
Noncurrent Member - License agreement with Ipsen Pharma SAS | 3,400,000 | — |
Long-term portion of operating lease liabilities | 2,850,000 | 2,592,000 |
Other long-term liability | 761,000 | 761,000 |
Total liabilities | 58,203,000 | 80,037,000 |
Stockholders' equity | ||
Common stock, $0.0001 par value; 500,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 102,431,933 and 101,116,162 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 10,000 | 10,000 |
Additional paid-in-capital | 1,081,315,000 | 1,056,738,000 |
Accumulated other comprehensive (loss) income | (92,000) | 84,000 |
Accumulated deficit | (620,399,000) | (554,081,000) |
Total stockholders' equity | 460,834,000 | 502,751,000 |
Additional Paid-in Capital | 1,081,315,000 | 1,056,738,000 |
Accumulated Other Comprehensive Income (Loss) | (92,000) | 84,000 |
Accumulated Deficit | (620,399,000) | (554,081,000) |
Common Stock | 10,000 | 10,000 |
Total liabilities and stockholders' equity | 519,037,000 | 582,788,000 |